Beta Bionics, Inc.

BBNX

Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
SEC CIK: 0001674632

SEC filings (opens in a new tab)

In the last 90 days, Beta Bionics, Inc. insiders filed 0 open-market purchases and 19 sales; 133 institutions reported holding it in 13F filings for Q2 2026, worth $752.4M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 13, 2026: $892.7M
Insider buysOpen market, last 90 days: 0
Insider sellsLast 90 days, $2.61M in total: 19
13F holdersQ2 2026, +6 vs. previous quarter: 133
13F valueReported value at the end of Q2 2026: $752.4M
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $100.3M; +53.9% year over year
Net income, FY2025: -$73.2M; No comparable prior period
Free cash flow, FY2025: -$56.2M; No comparable prior period
Revenue, Q3 FY2026: $35.5M; +30.3% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $73.2M (73.0% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 4.98M; Shares sold short
Change: −1.94M; −28.0% vs. previous
Days to cover: 3.94; At average daily volume

Superinvestors holding BBNX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding BBNX at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Beta Bionics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Nov 13, 2026 (view filing)4:01 PM ET	Nov 11	2 days	Feider StephenChief Financial Officer	SSale	−8.87K	$17.21	−$152.7K	−5.3%159.4K after	10b5-1
Nov 12, 2026 (view filing)4:45 PM ET	Nov 9	3 days	Feider StephenChief Financial Officer	SSale	−744	$17.00	−$12.6K	−0.5%159.4K after	10b5-1
Nov 9, 2026 (view filing)4:26 PM ET	Nov 5	4 days	Feider StephenChief Financial Officer	SSale	−382	$17.04	−$6.51K	−0.2%159.4K after	10b5-1
Nov 4, 2026 (view filing)4:08 PM ET	Nov 2	2 days	Hopman MarkChief Commercial Officer	SSale	−370	$16.90	−$6.25K	−0.7%54.1K after	10b5-1
Oct 29, 2026 (view filing)4:22 PM ET	Oct 27	2 days	Mensinger MikeChief Product Officer	SSale	−2.65K	$22.00	−$58.3K	−1.5%174.7K after	10b5-1
Oct 28, 2026 (view filing)4:03 PM ET	Oct 26	2 days	Hopman MarkChief Commercial Officer	SSale	−821	$20.00	−$16.4K	−1.5%54.5K after	10b5-1
Oct 16, 2026 (view filing)4:10 PM ET	Oct 14	2 days	Hopman MarkChief Commercial Officer	SSale	−775	$17.35	−$13.4K	−1.4%55.3K after
Oct 5, 2026 (view filing)5:11 PM ET	Oct 1	4 days	Hopman MarkChief Commercial Officer	SSale	−370	$18.96	−$7.02K	−0.7%56.1K after
Sep 23, 2026 (view filing)5:40 PM ET	Sep 22	1 day	Jones ChristyDirector	SSale	−6.43K	$23.00	−$147.9K	−24.7%19.6K after	10b5-1
Sep 18, 2026 (view filing)7:51 PM ET	Sep 9	9 days	Hopman MarkChief Commercial Officer	SSale	−36.0K	$18.46	−$664.6K	−29.0%88.0K after	Amended10b5-1

Top 10 13F holders, Q2 2026

See all 133 holders

The largest institutional positions in Beta Bionics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding BBNX in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
Eventide Asset Management, LLC	6,253,673	$98.1M	1.31%	+308,185+5.2%	Added
Soleus Capital Management, L.P.	4,393,714	$68.8M	2.37%	+39,213+0.9%	Added
Morgan Stanley	4,266,822	$66.9M	0.00%	+39,188+0.9%	Added
Sands Capital Ventures, LLC	3,708,043	$58.1M	9.47%	00.0%	Unchanged
BlackRock, Inc.	3,340,171	$52.3M	0.00%	+301,576+9.9%	Added
Point72 Asset Management, L.P.	2,254,683	$35.3M	0.05%	−270,357−10.7%	Reduced
Vanguard Capital Management LLC	1,782,346	$27.9M	0.00%	+54,369+3.1%	Added
Vestal Point Capital, LP	1,600,000	$25.1M	0.59%	−611,518−27.7%	Reduced
RTW Investments, LP	1,500,000	$23.5M	0.20%	−500,000−25.0%	Reduced
Deerfield Management Company, L.P. (Series C)	1,324,000	$20.7M	0.22%	00.0%	Unchanged

Holders of 5% or more of BBNX

See all 12 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Beta Bionics, Inc..

Largest holders of BBNX from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
Price T Rowe Associates Inc	13G	16.60%8.94M shares	New	Oct 7, 20261 filing	Oct 7, 2026	SEC
Eventide Asset Management, LLC	13G/A	13.40%5.95M shares	+2.08 ppfrom 11.32%	Feb 5, 20252 filings	May 15, 2026	SEC
Zone Healthcare Holdings, LLC	13G/A	9.90%4.31M shares	+2.00 ppfrom 7.90%	Feb 7, 20252 filings	Nov 12, 2025	SEC
Soleus Capital Group, LLC	13G/A	9.80%4.35M shares	–	May 8, 20261 filing	May 8, 2026	SEC
Soleus Capital Master Fund, L.P.	13G/A	8.70%4.83M shares	–	Nov 9, 20261 filing	Nov 9, 2026	SEC